INTRODUCTION
The silence information regulator or sirtuin (SIRT) family of class III histone deacetylases are NAD + -dependent deacetylases, while the class I and II histone deacetylases are Zn 2+ -dependent [1] . Seven mammalian homologues designated as SIRT-1 through SIRT-7 are identified to date. These sirtuins are found in distinct subcellular compartments where they regulate specific biological functions [2] .
Nuclear and cytosolic sirtuins
SIRT-1 and SIRT-2 are present both in the nucleus and in the cytoplasm. SIRT-1 deacetylates many nonhistone proteins involved in cell survival, metabolism and stress response [3] [4] [5] [6] [7] [8] . SIRT-2 is important for chromosomal stability during mitosis [9] . SIRT-6 is involved in the genomic stability, glucose homeostasis and inflammation [10] [11] [12] . SIRT-7 is found with nucleoli and condensed chromosomes [13] [14] .
Mitochondrial sirtuins
Three sirtuins namely SIRT-3, -4 and -5 are mitochondria enriched [15, 16] . SIRT-3 which is the most robust mitochondrial deacetylase [17] , is referred to as a mitochondrial stress sensor. SIRT-3 which is transported from nuclei to mitochondria upon cellular stress and plays a role in mitochondrial functioning by deacetylating acetyl-CoA synthethase [18, 19] .
SIRTUINS AND CARDIAC HYPERTROPHY
Angiotensin II (ANG II) has been considered as a potent stimulator of cardiac hypertrophy. Increased oxidative/nitrosative stress is a major component of the ANG II-mediated cell signaling contributing to cardiac hypertrophy. In mouse proximal tubular epithelial cells ANG II treatment lowers the expression levels of SIRT-3 and nicotinamide phosphoribosyltransferase (NAMPT), whose protein product increases mitochondrial NAD + , providing the co-substrate for SIRT-3. Candesartan, an ANG II type I receptor (AT 1 R) blocker, inhibits this effect [20] .
In rat vascular smooth muscle cells ANG II treatment increases SIRT-1 expression [21] . Miyazaki et al [22] reported that SIRT-1 inhibits the expression of AT 1 R in smooth muscle cells. SIRT-1 counteracts ANG IIinduced cardiomyocyte hypertrophy and reactive oxygen species (ROS)-dependent cell death [23] .
Reactive oxygen species and sirtuins
Knockout of the AT 1 R in mice increases life span by 26% and AT 1 R knockouts have lower levels of cardiac fibrosis, hypertrophy and attenuated aortic damage [20] . They also have lower levels of oxidative stress and increased mitochondrial density compared to controls. Mitochondrial ROS are indeed reduced by 55% by the overexpression of SIRT-3 and by 84% by the co-expression of SIRT-3 and manganese superoxide dismutase (Mn-SOD), whereas overexpression of SIRT-3 in Mn-SOD knockout cells causes no significant mitochondrial ROS reduction, suggesting that SIRT-3 enhances the activity of Mn-SOD to scavenge mitochondrial ROS [24] .
Overexpression of SIRT-3 in mouse embryonic fibroblasts (MEF's) reduces cellular ROS by 40%. However, reduction of cellular ROS mediated by SIRT-3 is blunted in Mn-SOD knockout MEF's, indicating that Mn-SOD is the major downstream mediator of SIRT-3 in reducing cellular ROS [25] . SIRT-3 has also been shown to decrease ROS production in brown adipocytes [26] .
SIRT-3 deficient mice develop cardiac hypertrophy and interstitial fibrosis at 8 weeks of age; on the other hand transgenic mice overexpressing SIRT-3 in the heart effectively block agonist-mediated hypertrophy. Cardiomyocytes cultured from SIRT-3 deficient hearts show increased ROS levels suggesting that SIRT-3 prevents cardiac hypertrophy response by scavenging cellular ROS [27] . Cells lacking SIRT-3 also exhibit an increase in mitochondrial superoxide levels when exposed to ischemia reperfusion [28] . In mice, the level of SIRT-1 in the heart is significantly upregulated after 2 and 4 weeks of pressure overload and by paraquat injection, which induces oxidative stress [29] .
Upon oxidative stress, SIRT-3 overexpression protects the cardiomyocytes against Bax-mediated apoptosis by deacetylating the substrate Ku70, promoting the binding of Ku70 to Bax, and hence blocking the Bax activation [30] . SIRT-3 also inhibits aging and makes the heart resistant to oxidative stress and heart failure. Mice lacking SIRT-3 develop severe age-related pathologies in the heart [31] .
Mitochondrial antioxidant enzymes and sirtuins
The sirtuin family has been demonstrated to play an important role in the regulation of mitochondrial function and in the activation of antioxidant defenses.
Mn-SOD is acetylated at Lys68 and this acetylation decreases Mn-SOD activity. In HEK293T cells mitochondrial SIRT-3 binds to, deacetylates and activates Mn-SOD. Increase of ROS levels stimulate SIRT-3 transcription, leading to Mn-SOD deacetylation and activation. Mn-SOD mediated ROS reduction is synergistically increased by SIRT-3 overexpression, but is cancelled by SIRT-3 depletion. Both SIRT-3 transcript and protein levels are induced by the generation of mitochondrial ROS [24] .
SIRT-3 deficiency and the associated mitochondrial protein hyperacetylation result in mitochondrial dysfunction [32] . In the SIRT-3 knockout mice, cardiac hypertrophy and the development of cardiac fibrosis are accelerated compared with SIRT-3-competent mice. In parallel, the absence of SIRT-3 results in the attenuation of antioxidant enzyme activities in response to the hypertrophic agents [33] . These data suggest that the antioxidant effects of SIRT-3 may play an important role in ameliorative hypertrophic agonistinduced cardiac hypertrophy [34] . This phenotype is also shown when pressure overload is directly induced by thoracic aortic constriction. The SIRT-3 knockout mice have a higher postoperative mortality from the banding studies compared with the wild-type mice and the knochout mice develop excessive age-associated hypertrophy and myocardial fibrosis [31] .
Qiu et al [25] showed that calorie restriction lowers oxidative stress by SIRT-3-mediated Mn-SOD activation. SIRT-3 overexpression in mouse embryonic fibroblasts lowers ROS levels in a Mn-SOD dependent manner. They [25] further showed that SIRT-3 interacts with Mn-SOD and that SIRT-3-mediated deacetylation of Mn-SOD increases its activity which provided protection against oxidative stress. Tao et al [28] confirmed that SIRT-3 regulates Mn-SOD activity and subsequent protection against ionizing radiation.
SIRT-3 also interacts and deacetylases cyclophilin D, a key component of the mitochondrial permeability transition pore (mPTP), thereby inhibiting mPTP opening. This in turn reduces oxidative stress and eventually slows down cardiac aging. [35] . SIRT-3 acts thus as sensor of ROS that can lead to mitochondrial damage and activates specific cellular signaling pathway to counteract oxidative stress such as the expression of Mn-SOD antioxidant protein [36] .
Taken together these data indicate that ROS levels are tightly controlled by SIRT-3 by increasing the activity of Mn-SOD [37] . In spontaneously hypertensive rats long-term histone deacetylase inhibition, independent of blood pressure response, reduces hypertrophic, proinflammatory and hypertensive responses by decreasing ROS and AT 1 R expression in the heart, indicating the importance of uncontrolled histone deacetylase activity in hypertension [38] .
In neonatal rat cardiomyocytes, SIRT-3 promotes nuclear localization of the Forkhead transcription factor FOXO3a, leading to enhanced transcription of the FOXO3a-dependent antioxidant gene Mn-SOD, thereby reducing cellular ROS levels [2, 27] . SIRT-1 also stimulates resistance to oxidative stress through FOXO in fibroblasts [39] .
In adult rat cardiac fibroblasts we have reported that ANG II increases superoxide anion production and intracellular and mitochondrial formation of reactive oxygen species [40] [41] [42] [43] . In rat vascular smooth muscle cells, FOXO3a interacts with the promoter of the Mn-SOD gene at a specific binding site [44] . The FOXO3a binding activity to the Mn-SOD and peroxiredoxin-3 (Prx-3) DNA is lower in nuclear extracts of ANG II-treated cardiac fibrtoblasts as compared to control fibroblasts [40, 44] . Upon phosphorylation of Akt (protein kinase B) by ANG II in cardiac fibroblasts we have shown that P-Akt is translocated from the cytosol to the nucleus and nuclear phosphorylation of FOXO3a by P-Akt leads to relocalization of FOXO3a form the nucleus to the cytosol, resulting in a decrease in its transcriptional activity and in the expression of the mitochondrial antioxidant enzymes Mn-SOD and Prx-3 [41, 45] .
A schematic description of the ANG II-induced release of ROS and FOXO3a dependent Mn-SOD and Prx-3 expression in cardiac fibroblasts is given in figure 1 .
Poly(ADP-ribose) polymerase-1 and sirtuins
Poly(ADP-ribose) polymerase-1 (PARP) is a 113 kDa multifunctional chromatin bound enzyme of the PARP family of proteins. PARP catalyzes the transfer of multiple ADP-ribose moieties from NAD + to the target proteins, through a process called poly-ADPribosylation, leading to depletion of cellular NAD + [46, 47] . Figure 1 . ANG II, through interaction with the AT1R, stimulates NAD(P)H oxidase in cardiac fibroblasts leading to an enhanced intracellular and mitochondrial (Mito) production of superoxide anion (O2
•-) and ROS. Upon phosphorylation of Akt (protein kinase B) by ANG II in cardiac fibroblasts, P-Akt is translocated from the cytoplasm to the nucleus and nuclear phosphorylation of the Forkhead box class O transcription factor FOXO3a by P-Akt leads to relocalization of FOXO3a from the nucleus to the cytosol, resulting in a decrease in Mn-SOD and Prx-3 expression. The effect of ANG II on sirtuin expression, intracellular GSH system, mitochondrial ATP-sensitive potassium channels (KATP) in cardiac fibroblasts has to be further elucidated. [SOD, superoxide dismutase; C, cytosol; N, nucleus; GSH, glutathione; Prx3, peroxiredoxin 3; MRP-1, multidrug resistance related protein-1; Trx, thioredoxin; FOXO, Forkhead box class O; Akt, protein kinase B; ↑, increase; ?, not known in cardiac fibroblasts.] PARP is activated during ANG II-induced cardiomyocyte hypertrophy and mice deficient in the PARP gene are protected from ANG II-mediated hypertrophy [48] . NAD + depletion, resulting from PARP overactivation, contributes to ANG II-mediated cardiac myocyte cell death [48] . This type of cell death is prevented by NAD + repletion, activation of the longevity factor SIRT-2α and by treatment with resveratrol [49] . Knocking down SIRT-2α levels by siRNA treatment eliminated the protective effect of resveratrol, thus indirectly indicating that PARP activation threatens cell survival by reducing the activity of NAD + -dependent class III histone deacetylases or sirtuins [2, 48] . PARP is thus a downstream nuclear target of ANG II-induced signaling pathway, contributing to cardiac hypertrophy and failure. PARP inhibition may be a novel therapeutic approach for the management of heart failure.
Finally, in hamsters treated with resveratrol, nuclear SIRT-1 induces mitochondrial Mn-SOD, which reduces oxidative stress and participitates in cardiomyocyte protection [50] . By enhancing nuclear SIRT-1 that increases Mn-SOD levels, resveratrol suppresses myoblast death induced by ANG II [50] . SIRT-1 activators such as resveratrol could be novel therapeutic tools for the treatment of chronic heart failure. Indeed, in high-fat-diet-fed mice the synthetic SIRT-1 activator SRT1720 significantly reduces the number of ischemic foci in the heart and attenuates inflammatory gene expression in the heart [51] .
CONCLUSIONS AND FUTURE PERSPECTIVES
Sirtuins play diverse roles in the cardiovascular system. This functional diversity is related to the existence of seven mammalian sirtuins and to the various molecular targets for its deacetylation and ADP ribosyltransfer reactions. In the heart SIRT-3 blocks the development of cardiac hypertrophy and protect cardiomyocytes from oxidative stress-mediated cell death. The antioxidant effect of SIRT-3 may play an important role in ameliorative hypertrophic agonist-induced cardiac hypertrophy. SIRT-3 is an endogenous negative regulator of cardiac hypertrophy by suppressing the cellular production of ROS. Undoubtedly, more research is needed to unravel the exact role of sirtuins in cardiac cell biology before they can be used as therapeutic targets valuable for translational medicine and heart failure. Whether the direct pharmacological modulation of sirtuins may confer greater benefit in cardiac diseases than the other antioxidant approaches, which shows disappointing results, is an intriguing concept.
